Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

被引：0
|
作者：
Jennifer Pascoe
Aimee Jackson
Charlotte Gaskell
Claire Gaunt
Joyce Thompson
Lucinda Billingham
Neil Steven
机构：
[1] Queen Elizabeth Hospital Birmingham,Cancer Research UK Clinical Trials Unit (CRCTU)
[2] University of Birmingham,undefined
[3] Birmingham Heartlands Hospital,undefined
[4] Bordesley Green E,undefined
[5] Institute of Immunology and Immunotherapy,undefined
[6] College of Medical and Dental Sciences,undefined
[7] University of Birmingham,undefined
来源：
BMC Cancer | / 21卷
关键词：
Cachexia; Advanced lung cancer; Nutritional supplement; Supportive care; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 19 条
  • [1] Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
    Pascoe, Jennifer
    Jackson, Aimee
    Gaskell, Charlotte
    Gaunt, Claire
    Thompson, Joyce
    Billingham, Lucinda
    Steven, Neil
    BMC CANCER, 2021, 21 (01)
  • [2] Effect of beta-hydroxy beta-Methylbutyrate/arginine/glutamine (HMB/Arg/GIn) on lean body mass (LBM), in patients with advanced lung cancer
    Pascoe, Jennifer S.
    Thompson, Joyce
    Joseph, Julie
    Gaunt, Claire
    Bowden, Sarah Jane
    Houlton, Aimee
    BillIngham, Lucinda
    Brooks, Cassandra
    Irwin, Amanda
    Steven, Neil Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    Rittmeyer, Achim
    Barlesi, Fabrice
    Waterkamp, Daniel
    Park, Keunchil
    Ciardiello, Fortunato
    von Pawel, Joachim
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Kowalski, Dariusz M.
    Dols, Manuel Cobo
    Cortinovis, Diego L.
    Leach, Joseph
    Polikoff, Jonathan
    Barrios, Carlos
    Kabbinavar, Fairooz
    Frontera, Osvaldo Aren
    De Marinis, Filippo
    Turna, Hande
    Lee, Jong-Seok
    Ballinger, Marcus
    Kowanetz, Marcin
    He, Pei
    Chen, Daniel S.
    Sandler, Alan
    Gandara, David R.
    LANCET, 2017, 389 (10066): : 255 - 265
  • [4] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    Fehrenbacher, Louis
    Spira, Alexander
    Ballinger, Marcus
    Kowanetz, Marcin
    Vansteenkiste, Johan
    Mazieres, Julien
    Park, Keunchil
    Smith, David
    Artal-Cortes, Angel
    Lewanski, Conrad
    Braiteh, Fadi
    Waterkamp, Daniel
    He, Pei
    Zou, Wei
    Chen, Daniel S.
    Yi, Jing
    Sandler, Alan
    Rittmeyer, Achim
    LANCET, 2016, 387 (10030): : 1837 - 1846
  • [5] OPEN-LABEL, RANDOMISED MULTICENTRE, PHASE II TRIAL OF ORAL VINORELBINE (NVBO) OR INTRAVENOUS VINORELBINE (NVBIV) WITH CISPLATIN (CDDP) IN PATIENTS (PTS) WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): A CHINESE EXPERIENCE
    Zhang, Li
    Chang Jianhua
    Huang, Cheng
    Wang, Jie
    Shu Yongqian
    Zhang, Yiping
    Burillon, Jean-Philippe
    Pouget, Jean-Christophe
    Riggi, Marcello
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1167 - S1167
  • [6] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (vol 389, pg 255, 2016)
    Rittmeyer, A.
    Barlesi, F.
    Waterkamp, D.
    LANCET, 2017, 389 (10077): : E5 - E5
  • [7] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (vol 389, pg 255, 2017)
    Rittmeyer, A.
    Barlesi, F.
    Waterkamp, D.
    LANCET, 2017, 389 (10068): : E2 - E2
  • [8] Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
    Yang, Mao
    Zhao, Yuhao
    Li, Yongsheng
    Cui, Xuya
    Liu, Fatao
    Wu, Wenguang
    Wang, Xu-An
    Li, Maolan
    Liu, Yun
    Liu, Yingbin
    BMJ OPEN, 2023, 13 (02):
  • [9] Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Gladkov, Oleg
    Clingan, Philip
    Sriuranpong, Virote
    Rizvi, Naiyer
    Gao, Bo
    Li, Siyu
    Lee, Sue
    McGuire, Kristina
    Chen, Chieh-, I
    Makharadze, Tamta
    Paydas, Semra
    Nechaeva, Marina
    Seebach, Frank
    Weinreich, David M.
    Yancopoulos, George D.
    Gullo, Giuseppe
    Lowy, Israel
    Rietschel, Petra
    LANCET, 2021, 397 (10274): : 592 - 604
  • [10] Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial
    Eduardo Lopez-Cortes, Luis
    Rosso-Fernandez, Clara
    Nunez-Nunez, Maria
    Lavin-Alconero, Lucia
    Bravo-Ferrer, Jose
    Barriga, Angel
    Delgado, Mercedes
    Lupion, Carmen
    Retamar, Pilar
    Rodriguez-bano, Jesus
    BMJ OPEN, 2017, 7 (06):
12